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Abstract
BACKGROUND: Screening to identify individuals with 
elevated brain amyloid (Aβ+) for clinical trials in Preclinical 
Alzheimer’s Disease (PAD), such as the Anti-Amyloid 
Treatment in Asymptomatic Alzheimer’s disease (A4) trial, 
is slow and costly.  The Trial-Ready Cohort in Preclinical/
Prodromal Alzheimer’s Disease (TRC-PAD) aims to accelerate 
and reduce costs of AD trial recruitment by maintaining a 
web-based registry of potential trial participants, and using 
predictive algorithms to assess their likelihood of suitability for 
PAD trials.
OBJECTIVES:  Here we describe how algorithms used to predict 
amyloid burden within TRC-PAD project were derived using 
screening data from the A4 trial.
DESIGN:  We apply machine learning techniques to predict 
amyloid positivity. Demographic variables, APOE genotype, 
and measures of cognition and function are considered as 
predictors.  Model data were derived from the A4 trial.
SETTING: TRC-PAD data are collected from web-based and 
in-person assessments and are used to predict the risk of 
elevated amyloid and assess eligibility for AD trials.  
PARTICIPANTS:  Pre-randomization, cross-sectional data from 
the ongoing A4 trial are used to develop statistical models.
MEASUREMENTS: Models use a range of cognitive tests and 
subjective memory assessments, along with demographic 
variables. Amyloid positivity in A4 was confirmed using 
positron emission tomography (PET).
RESULTS: The A4 trial screened N=4,486 participants, of which 
N=1323 (29%) were classified as Aβ+ (SUVR ≥ 1.15). The Area 
under the Receiver Operating Characteristic curves for these 
models ranged from 0.60 (95% CI 0.56 to 0.64) for a web-based 
battery without APOE to 0.74 (95% CI 0.70 to 0.78) for an 
in-person battery. The number needed to screen to identify an 
Aβ+ individual is reduced from 3.39 in A4 to 2.62 in the remote 
setting without APOE, and 1.61 in the remote setting with 
APOE.
CONCLUSIONS:  Predictive algorithms in a web-based registry 
can improve the efficiency of screening in future secondary 
prevention trials. APOE status contributes most to predictive 
accuracy with cross-sectional data. Blood-based assays of 
amyloid will likely improve the prediction of amyloid PET 
positivity.
Key words:  Trial-ready cohort, Alzheimer’s disease, machine learning.
Background
Screening cognitively normal older individuals for the presence of elevated cerebral amyloid-beta protein (“Aβ+”) and inclusion in secondary 
prevention trials for Alzheimer’s disease (AD) is invasive, 
expensive and slow. The current gold standards to 
measure Amyloid-β in the brain require either positron 
emission tomography (PET) or cerebrospinal fluid (CSF) 
assay. For example, the Anti-Amyloid Treatment in 
Asymptomatic Alzheimer’s disease (A4) trial conducted 
amyloid PET on 4,486 individuals in order to identify 
1,323 Aβ+ individuals for an amyloid PET screen fail 
rate of 71% (1). The Number Needed to Screen (NNS) to 
identify each Aβ+ individual was 3.39 individuals.       
Trial-Ready Cohort in Preclinical/Prodromal 
Alzheimer’s Disease (TRC-PAD) is a research program 
that was initiated to find solutions to these challenges in 
trial recruitment and site management, as described in 
Aisen, et al. Submitted (2). There are three elements that 
make up the TRC-PAD platform;  Alzheimer’s Prevention 
Trial (APT) webstudy (aptwebstudy.org), Site Referral 
System (SRS) and the Trial Ready Cohort (TRC). The APT 
webstudy invites participants to enroll into the study. 
At the time of enrollment, participants are asked for 
demographic, medical and lifestyle information.  They 
are asked to complete longitudinal web-based cognitive 
testing and symptom questionnaires. With these data, 
we aim to estimate the likelihood that an individual is 
Aβ+ before they are invited to participate in a secondary 
prevention trial.  The SRS helps facilitate the participants 
deemed to be most likely Aβ+ from APT to go for 
in-clinic assessments where they proceed with the TRC 
screening.  During the TRC screening phase participants 
are administered additional testing, including Preclinical 
Alzheimer’s Cognitive Composite (PACC) (3) and 
genotyping, before assessing their eligibility for an 
amyloid test.  
In this paper, we describe how the prediction models 
and algorithms used in TRC-PAD were derived from A4 
© The Author(s)
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screening data. We anticipate blood-based biomarkers 
will greatly improve predictions of amyloid positivity, 
and this is a focus of future work and an aim of TRC-
PAD. Predictors in the current analysis are limited to 
demographics, cognitive and functional assessments, and 
APOE genotype.
Methods
Population and Study Design
The study design and screening data for A4 have 
been previously described (7, 8) and Institutional Review 
Boards have approved both A4 and TRC-PAD studies. 
The A4 screening dataset contains N=4,486 participants, 
of which 1323 (29%) were classified as Aβ+. Amyloid 
PET imaging was conducted with florbetapir F18 and 
summarized by mean cortical standardized uptake 
value ratio (SUVR) relative to the whole cerebellum. 
Participants were considered eligible to continue 
screening for A4 based on an algorithm combining both 
quantitative SUVR (≥1.15) and qualitative visual read 
performed at a central laboratory. A SUVR between 
1.10 and 1.15 was considered to be elevated amyloid 
only if the visual read was considered positive by a 
two-reader consensus determination.  Participants who 
were considered Aβ+ were slightly older; with mean/
standard deviation (SD) age of 72.10/4.89 in the Aβ+ 
group and 70.95/4.53 in the Aβ- group. However, there 
were no observed differences in sex and education.  Aβ+ 
participants were more likely to have a family history of 
dementia and at least one APOEε4 allele.  In addition, 
Aβ+ participants performed worse on the screening 
Preclinical Alzheimer Cognitive Composite (PACC) 
results and had higher scores on the Cognitive Function 
Index.
Variables
Table 1 describes the collections of predictors that we 
considered to train different predictive algorithms. All 
screening data for the A4 Study were collected during 
supervised clinic visits. However some components of 
the A4 screening battery are being captured remotely 
in the APT webstudy, including demographic, Cogstate 
brief battery (9), family history (sibling or parent with 
Alzheimer’s), and Cognitive Function Instrument 
(10) (CFI) variables indicated in Table 1. We consider 
predictive algorithms using these “remote” variables 
only, as well as a more thorough battery that would 
require a supervised clinic visit with an administration 
of the PACC3. In all, we considered 6 models: (1) remote 
battery without APOE, (2) remote battery with APOE, 
(3) in clinic battery without APOE, (4) in clinic battery 
with APOE, (5) in clinic battery with individual PACC 
component scores without  APOE, and (6) in clinic 
battery with individual PACC component scores with 
APOE. The PACC component scores include the Mini-
Mental State Exam (MMSE) (11), Wechsler Memory Scale-
Revised Logical Memory, Digit Symbol Substitution 
Table 1. Predictors Considered 
Abbreviation Variable Description Remote In Clinic
Age Age Number of years √ √
Edu Education Number of years √ √
Sex Sex Male or Female √ √
OCL Cogstate One Card Learning Accuracy √
OBR Cogstate One Back Reaction Reaction time √
DER Cogstate Detection Reaction Reaction time √
IDR Cogstate Identification Reaction Reaction time √
FH Family History Family history a parent or sibling with AD √
FH P Family History - Parent Family history a parent with AD √
FH S Family History - Sibling Family history a sibling with AD √
CFI Pt Cognitive Function Instrument - Participant √ √
CFI SP Cognitive Function Instrument - Study Partner √
ADL Pt Activities of Daily Living - Participant √
ADL SP Activities of Daily Living - Study Partner √
PACC Preclinical Alzheimer Cognitive Composite √
APOE4 APOEε4 (X/ √) (X/ √)
We considered predictive algorithms which could be applied to data captured either remotely via a web-based registry, or in the clinic (though all data in A4 was collected 
in clinic), as indicated in the table. In all we considered 6 models: (1) remote battery with APOE, (2) remote battery without APOE, (3) in clinic battery with APOE, (4) in 
clinic battery without APOE, (5) in clinic battery with individual PACC component scores and  APOE, and (6) in clinic battery with individual PACC component scores 
without APOE.
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(DSST), and Free and Cued Selective Reminding Test 
(FCSRT) (12).
Statistical Analysis
Extreme Gradient Boosting (XGBoost) (4) is a decision 
tree-based machine learning technique (6). A single 
decisions tree, or regression tree, is easy to interpret 
but provides relatively poor prediction. Aggregating a 
large number of trees can improve prediction accuracy. 
Boosting is a technique in which models are trained 
in sequence, with each new model making cumulative 
improvements. At each iteration the data are re-weighted 
such that misclassified data points receive larger weights. 
XGBoost is a scalable tree boosting algorithm, that is 
optimized and designed to be highly efficient, flexible, 
and portable. 
XGBoost supports monotone constraints and 
customized objective functions. We applied monotone 
constraints to predictors such as age, number of 
APOEε4 alleles (0, 1 or 2), and assessment scores that 
we expect to have a generally monotonic relationship 
with amyloid PET SUVR (Supplemental Figure 1). The 
Figure 1. Contribution of 5 best predictors in each model
Using the model training data we see the contribution to prediction accuracy expressed in terms of the mean absolute SHAP value (mean|SHAP|). Abbreviations: SHAP, 
SHapley Additive explanation; OCL, One Card Learning; OBR, One Back Reaction; DER, Detection Reaction; IDR, Identification Reaction; FH, Family History; FH P, FH 
Parent; FH S, FH Sibling; CFI, Cognitive Function Index; CFI Pt, CFI Participant; CFI SP, CFI Study Partner; ADL, Activities of Daily Living; ADL Pt, ADL Participant; ADL 
SP, ADL Study Partner; PACC, Preclinical Alzheimer Cognitive Composite
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default XGBoost objective function is mean squared 
loss, meaning decision trees are selected to minimize 
the residual sum of squares. Because XGBoost does 
not provide confidence intervals with mean squared 
loss, we applied the Quantile Regression loss function 
to estimate the 50%, 2.5%, and 97.5% quantiles of the 
predictions. XGBoost model has a number of hyper-
parameters that are used to assist in the issue known as 
the bias-variance trade-off (13). Hyper-parameters are 
fixed before the model is fitted and are not learned from 
data. We used 10-fold Cross-Validation (CV) to assess 
the out-of-sample bias and variance for given hyper-
parameter values, and Bayesian Optimization (14) to 
optimize the hyper-parameter selection. We use SHapley 
Additive exPlanation (SHAP) (15) values to summarize 
the importance of each predictor to the overall predictive 
accuracy of each model. More details about the model 
fitting procedures are provided in the supplemental 
material (Supplemental Table 1). Our main interest lies in 
the predictive accuracy of the models. In order to assess 
this, we split the data randomly into 80% training and 
20% test. After fitting the models with the training data, 
we assess their predictive accuracy with the independent 
test data. Analyses were conducted with R version 3.6.2 
(r-project.org) with packages xgboost (4) version 0.90.0.2 
and mlrMBO (16) version 1.1.2.
Table 2. Operating characteristics of screening algorithms using the test data with Aβ+ set to SUVR ≥ 1.15 
Model SUVR Threshold Accuracy Sensitivity Specificity NPV PPV NNS
Remote 1.05 54.88% 60.70% 52.77% 78.72% 31.81% 3.14
Remote with APOE 1.04 61.86% 74.24% 57.37% 85.99% 38.72% 2.58
In Clinic 1.04 57.21% 62.45% 55.31% 80.23% 33.65% 2.97
In Clinic with APOE 1.04 62.33% 73.80% 58.16% 85.95% 39.03% 2.56
In Clinic PACC 1.04 56.63% 58.95% 55.78% 78.92% 32.61% 3.07
In Clinic PACC with APOE 1.04 62.67% 73.80% 58.64% 86.05% 39.30% 2.54
Remote 1.15 71.98% 10.04% 94.45% 74.31% 39.66% 2.52
Remote with APOE 1.15 77.09% 35.81% 92.08% 79.81% 62.12% 1.61
In Clinic 1.15 72.44% 5.68% 96.67% 73.85% 38.24% 2.62
In Clinic with APOE 1.15 76.51% 36.24% 91.13% 79.75% 59.71% 1.67
In Clinic PACC 1.15 73.60% 6.55% 97.94% 74.28% 53.57% 1.87
In Clinic PACC with APOE 1.15 75.00% 28.38% 91.92% 77.96% 56.03% 1.78
The top half of the table provides operating characteristics when a threshold is applied to predicted amyloid PET SUVR that results in a 50% prediction prevalence (half of 
the screening pool is predicted positive and tested with a PET scan). The first column indicates the threshold required to attain 50% prediction prevalence. The bottom half 
of the table applies a threshold of 1.15, which reduces Number Need to Screen (NNS), but also greatly reduces sensitivity.  The NNS is the inverse of the Positive Predictive 
Value (PPV).  The PPV indicates the percentage of participants that are truly positive when the model indicates them as positive.  Likewise, the Negative Predictive Value 
(NPV), this gives the probability that a participant is truly amyloid negative when the model indicates them as negative.
Table 3. Demographic characteristics of amyloid positive selections from the test data with Aβ+ set to SUVR ≥ 1.15
APOE4 Family History Sex
Model SUVR Threshold 0 1 2 No Yes Female Male
Remote 1.05 298 (68.19%) 123 (28.15%) 16 (3.66%) 140 (32.04%) 297 (67.96%) 248 (56.75%) 189 (43.25%)
Remote with APOE 1.04 169 (38.50%) 240 (54.67%) 30(6.83%) 117 (26.65%) 322 (73.35%) 248 (56.49%) 191 (43.51%)
In Clinic 1.04 283 (66.59%) 128 (30.12%) 14 (3.29%) 112 (26.35%) 313 (73.65%) 248 (58.35%) 177 (41.65%)
In Clinic with APOE 1.04 175 (40.42%) 228 (52.66%) 30 (6.93%) 120 (27.71%) 313 (72.29%) 240 (55.43%) 193 (44.57%)
In Clinic PACC 1.04 281 (67.87%) 119 (28.74%) 14 (3.38%) 106 (25.60%) 308 (74.40%) 246 (59.42%) 168 (40.58%)
In Clinic PACC with APOE 1.04 177 (41.16%) 223 (51.86%) 30 (6.98%) 100 (23.26%) 330 (76.74%) 256 (59.53%) 174 (40.47%)
Remote 1.15 39 (67.24%) 17 (29.31%) 2 (3.45%) 6 (10.34%) 52 (89.66%) 27 (46.55%) 31 (53.45%)
Remote with APOE 1.15 6 (4.55%) 96 (72.73%) 30 (22.73%) 30 (22.73%) 102 (77.27%) 67 (50.76%) 65 (49.24%)
In Clinic 1.15 26 (76.47%) 8 (23.53%) 0 (0.00%) 7 (20.59%) 27 (79.41%) 15 (44.12%) 19 (55.88%)
In Clinic with APOE 1.15 22 (15.83%) 88 (63.31%) 29 (20.86%) 34 (24.46%) 105 (75.54%) 67 (48.2%) 72 (51.80%)
In Clinic PACC 1.15 16 (57.14%) 12 (42.86%) 0 (0.00%) 4 (14.29%) 24 (85.71%) 16 (57.14%) 12 (42.86%)
In Clinic PACC with APOE 1.15 18 (15.52%) 68 (58.62%) 30 (25.86%) 27 (23.28%) 89 (76.72%) 55 (47.41%) 61 (52.59%)
The top half of the table provides demographic characteristics when a threshold is applied to predicted amyloid PET SUVR that results in a 50% prediction prevalence 
(half of the screening pool is predicted positive and tested with a PET scan). The first column indicates the threshold required to attain 50% prediction prevalence. The 
bottom half of the table applies a threshold of 1.15.  We can see in all the scenarios where APOE is included in the model, at least 29 of the 30 participants with APOE4 2 
allele (in the test data) have been selected.
PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALS
217
Results
Figure 1 shows the relative contributions, in terms 
of SHAP values, for each predictor to the predictive 
accuracy of each model. As expected, when available, 
APOE genotype is the most important predictor for these 
cross-sectional models. We see that age, CFI, education, 
and family history also enter the top 5 most valuable 
predictors in some models. Figure 2, the Receiver 
Operating Characteristic (ROC) curves and Area under 
the Curve (AUC) for the 6 models, also demonstrates 
the relative value of APOE. The dashed lines are models 
fitted without the APOEε4 variable and the solid lines 
are for models that include APOEε4. The ROC curves 
were generated using a cut point SUVR value of 1.15 
for a binary separation between amyloid positive and 
negative. In general, we see AUCs in the range 0.60 
(without APOE) to 0.73 (with APOE). 
Figure 3 expresses prediction accuracy in terms of 
screening for a clinical trial. The top panel shows 1/
Positive Predictive Value (PPV), which is equivalent 
to the number needed to screen (with amyloid PET) to 
identify one eligible participant. In this figure, movement 
along the horizontal axis represents varying the threshold 
applied to SUVRs predicted from each model. The 
bottom panel provides the required number of potential 
participants (e.g. webstudy participants) in order to 
identify 1,000 Aβ+ participants. 
Table 2 reports operating characteristics from several 
screening algorithm scenarios. The top half provides 
operating characteristics when a threshold is selected to 
provide 50% prediction prevalence (i.e. select half the 
participant pool to receive amyloid PET scans). With 50% 
prediction prevalence, the NNS is about 2.5 participants 
with APOE and 3.0 participants without APOE. When 
the threshold for predicted amyloid PET is increased to 
1.15, the NNS is reduced to about 1.7 participants with 
APOE and 2.5 participants without APOE. However, this 
results in much lower sensitivity, and as we can see from 
Figure 3, a threshold of 1.15 would be practical only with 
participant registries of 10,000-13,000 to identify 1,000 
Aβ+ participants.
Discussion
This work, in the context of the TRC-PAD platform, 
can facilitate the development of participant selection 
algorithms.  TRC-PAD has two main selection points; the 
first is from the APT webstudy to in-clinic assessment 
(stage 1) and the second is from in-clinic to amyloid 
testing (stage 2). In stage 1, consented webstudy 
participants are referred to their nearest TRC-PAD site, 
identified via the use of self-reported zip codes.  They are 
then ranked based on their SUVR prediction.  In addition 
to this predicted SUVR, the selection process considers 
demographics to achieve diversity and if the participant 
has known prior amyloid testing and results.  During 
the first in-clinic visit of the referred participants in stage 
1, additional cognitive testing, in the form of the PACC, 
and APOE genotyping is performed.  With this additional 
information, the SUVR predictions are updated and 
presented for central authorization of amyloid testing.  
This work has shown that by collecting relatively 
simple demographics, cognitive and functional 
assessments remotely, via the webstudy, we will be able 
to reduce screen fail rates and improve enrollment.  Even 
small improvements in NNS can have a large impact 
on the expense of screening for Preclinical AD clinical 
trials. For example, assuming a conservative estimate 
of 3,500 US Dollars (USD) per scan, the A4 study spent 
Figure 2. ROC curves and AUCs
ROCs and AUCs for each model are determined using the independent test set and 
Aβ+ set to SUVR ≥ 1.15.  The colors represent the setting type; Remote (red), In-Cli-
nic (blue) and PACC components (blue). Abbreviations: ROC, Receiver Operating 
Characteristic; AUC, Area Under the Curve; PACC, Preclinical Alzheimer Cognitive 
Composite
Figure 3. Number needed to screen and required 
registry size
The top panel shows the number needed to screen (which is equivalent to 1/PPV) 
with amyloid PET to identify one Aβ+ individual by applying the given SUVR 
threshold to the values predicted from each model. The middle panel shows sen-
sitivity. The models not containing APOEε4 all have lower sensitivity. The bottom 
panel shows the size of the screening pool (e.g. web-based registry) that would be 
required to recruit 1,000 Aβ+ individuals by applying the given SUVR threshold to 
values predicted from each model.
Abbreviations: PPV, Positive Predictive Value; SUVR, Standardized Uptake Value 
Ratio; PACC, Preclinical Alzheimer Cognitive Composite; PET, positron emission 
tomography
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a total of about 4,486x3,500(USD) = 15,701,000(USD) for 
screening amyloid PET scans alone to identify 1,323 Aβ+ 
individuals (NNS=3.39).  Reducing the NNS from 3.39 
to 2.62, which seems plausible with the simplest remote 
battery, would have reduced this cost by 3,569,090(USD) 
to 1,323x2.62x3,500(USD) = 12,131,910 (USD).  In addition 
to the remote data setting, this work included the value 
of APOE genotyping and collection of PACC during 
an in-clinic screening.  Adding APOE genotype might 
reduce NNS to below 2.00, for a total PET screening cost 
of 1,323x2.00x3,500(USD) = 9,261,000(USD).  The financial 
impact would be less with a cerebrospinal fluid (CSF)-
based, or blood-based, amyloid screen, but the impact 
on subject and site burden would remain significant. 
From a statistical aspect, we have demonstrated the use 
of Machine Learning Techniques to both optimize, via 
Bayesian Optimization, and produce predictive models 
using XGBoost.  We have illustrated how to make 
inferences from a modelling approach that is primarily 
used for prediction via the SHAP metric.
One limitation of these pre-screening algorithms is 
that the cohort characteristics will be impacted. For 
example, we would expect the algorithms to produce an 
older cohort with an even greater proportion of APOEε4 
carriers than a cohort selected without a pre-screen. This 
could be mitigated by stratifying the screening process 
to ensure an adequate sample of younger, APOEε4 non-
carriers; but with adverse effects on the NNS.  Another 
consideration is the inability for these models to 
extrapolate beyond the data in the continuous variables 
such as age.  A second potential limitation is in the bias of 
the training data.  As we start using these models in TRC-
PAD and collect additional data, we will assess whether 
the models are biased against any additional covariates 
collected.
Future work will focus on utilizing longitudinal 
cognitive and functional change and/or the use of blood-
based biomarkers to improve the performance of these 
predictive models and algorithms. We anticipate, based 
on analyses of the Alzheimer Disease Neuroimaging 
Initiative (ADNI) (5), that longitudinal change may be a 
valuable predictor of amyloid status.  In addition, we will 
incorporate plasma amyloid peptide ratios (currently in 
validation testing) into the final stage of prediction and 
expect a large improvement in prediction.
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